Hikal Overview

  • Year Founded
  • 1988

Year Founded

  • Status
  • Public

  • Employees
  • 3,468

Employees

  • Stock Symbol
  • 524735

Stock Symbol

  • Share Price
  • $4.15
  • (As of Friday Closing)

Hikal General Information

Description

Hikal Ltd manufactures chemical intermediates, specialty chemicals, active pharmaceutical ingredients, and contract research activities. Its products are distributed to the pharmaceutical, biotech, agrochemical, and specialty chemical industries. Its segments include Crop Protection and Pharmaceuticals. The majority of the revenue is derived from the pharmaceutical segment.

Contact Information

Website
www.hikal.com
Formerly Known As
Hikal Chemicals Industries Private limited, Hikal Chemicals Industries Limited
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Great Eastern Chambers
  • Sector 11, CBD-Belapur, Navi Mumbai
  • Mumbai, Maharashtra 400614
  • India
+91 022
Primary Industry
Specialty Chemicals
Other Industries
Pharmaceuticals
Horticulture
Stock Exchange
BOM
Vertical(s)
Corporate Office
  • Great Eastern Chambers
  • Sector 11, CBD-Belapur, Navi Mumbai
  • Mumbai, Maharashtra 400614
  • India
+91 022

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hikal Stock Performance

As of 20-Jun-2025, Hikal’s stock price is $4.15. Its current market cap is $512M with 123M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.15 $4.15 $3.64 - $5.49 $512M 123M 33.6K $0.09

Hikal Financials Summary

As of 31-Mar-2025, Hikal has a trailing 12-month revenue of $218M.

In Thousands,
USD
TTM 31-Mar-2025 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023
EV 664,365 664,365 478,632 496,776
Revenue 218,027 218,027 213,648 249,659
EBITDA 39,430 39,430 32,554 31,552
Net Income 10,739 10,739 8,407 9,761
Total Assets 295,642 295,642 298,243 290,555
Total Debt 89,398 89,398 98,038 91,130
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Hikal Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hikal‘s full profile, request access.

Request a free trial

Hikal Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Hikal Ltd manufactures chemical intermediates, specialty chemicals, active pharmaceutical ingredients, and contract rese
Specialty Chemicals
Mumbai, India
3,468 As of 2024

Darmstadt, Germany
 

Ahmedabad, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Hikal Competitors (6)

One of Hikal’s 6 competitors is Merck, a Corporation company based in Darmstadt, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Merck Corporation Darmstadt, Germany
Zydus Lifesciences Corporation Ahmedabad, India
Lanxess Deutschland Corporation Cologne, Germany
Taro Pharmaceutical Industries Corporate Backed or Acquired Haifa Bay, Israel
Evonik Industries Formerly PE-Backed Essen, Germany
To view Hikal’s complete competitors history, request access »

Hikal Patents

Hikal Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3156529-A1 Substantially pure clarithromycin 9-oxime and its preparation thereof Pending 29-Oct-2019
EP-4051289-A1 Substantially pure clarithromycin 9-oxime and its preparation thereof Inactive 29-Oct-2019
US-20230250124-A1 Substantially pure clarithromycin 9-oxime and its preparation thereof Pending 29-Oct-2019
EP-4051289-A4 Substantially pure clarithromycin 9-oxime and its preparation thereof Inactive 29-Oct-2019
CA-3153357-A1 An industrial scale process for the preparation of prothioconazole Pending 17-Oct-2019 A01N43/653
To view Hikal’s complete patent history, request access »

Hikal Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hikal ESG

Risk Overview

Risk Rating

Updated October, 15, 2024

37.43 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,673

Rank

Percentile

Pharmaceuticals

Industry

of 844

Rank

Percentile

Pharmaceuticals

Subindustry

of 419

Rank

Percentile

To view Hikal’s complete esg history, request access »

Hikal FAQs

  • When was Hikal founded?

    Hikal was founded in 1988.

  • Where is Hikal headquartered?

    Hikal is headquartered in Mumbai, India.

  • What is the size of Hikal?

    Hikal has 3,468 total employees.

  • What industry is Hikal in?

    Hikal’s primary industry is Specialty Chemicals.

  • Is Hikal a private or public company?

    Hikal is a Public company.

  • What is Hikal’s stock symbol?

    The ticker symbol for Hikal is 524735.

  • What is the current stock price of Hikal?

    As of 20-Jun-2025 the stock price of Hikal is $4.15.

  • What is the current market cap of Hikal?

    The current market capitalization of Hikal is $512M.

  • What is Hikal’s current revenue?

    The trailing twelve month revenue for Hikal is $218M.

  • Who are Hikal’s competitors?

    Merck, Zydus Lifesciences, Lanxess Deutschland, Taro Pharmaceutical Industries, and Evonik Industries are some of the 6 competitors of Hikal.

  • What is Hikal’s annual earnings per share (EPS)?

    Hikal’s EPS for 12 months was $0.09.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »